Limits...
Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage III colon cancer.

Jeong WK, Shin JW, Baek SK - Ann Surg Treat Res (2015)

Bottom Line: Although adjuvant chemotherapy reduces the risk of disease recurrence in stage III colon cancer patients, published guidelines do not specify when it should be initiated.The mean disease-free survival of patients receiving adjuvant therapy earlier was 54.6 months, whereas that of patients with later treatment was 43.5 months (P = 0.014).However, no significant differences in overall survival were observed between the 2 groups.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Keimyung University Dongsan Medical Center, Daegu, Korea.

ABSTRACT

Purpose: Although adjuvant chemotherapy reduces the risk of disease recurrence in stage III colon cancer patients, published guidelines do not specify when it should be initiated. This study aimed to assess the effect of adjuvant chemotherapy initiation time on disease recurrence and survival in stage III colon cancer patients undergoing curative surgical resection.

Methods: The medical records of stage III colon cancer patients undergoing curative resection between February 2004 and December 2009 were reviewed.

Results: Of the 133 enrolled patients, 27 (20.3%) began adjuvant chemotherapy within 3 weeks of surgery, whereas 106 (79.7%) did after 3 weeks following surgery. Patients receiving chemotherapy within 3 weeks of surgery were less likely to experience recurrences than those beginning treatment later (11.1% vs. 33%, P = 0.018). The mean disease-free survival of patients receiving adjuvant therapy earlier was 54.6 months, whereas that of patients with later treatment was 43.5 months (P = 0.014). However, no significant differences in overall survival were observed between the 2 groups.

Conclusion: Adjuvant chemotherapy should be initiated as soon as a patient's clinical condition allows. Patients with stage III colon cancer may benefit from adjuvant chemotherapy initiated within 3 weeks of surgery.

No MeSH data available.


Related in: MedlinePlus

Disease-free survival rates of both groups. Group A, patients receiving chemotherapy within 3 weeks of surgery; group B, patients receiving chemotherapy after 3 weeks of surgery.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4559614&req=5

Figure 2: Disease-free survival rates of both groups. Group A, patients receiving chemotherapy within 3 weeks of surgery; group B, patients receiving chemotherapy after 3 weeks of surgery.

Mentions: Group A patients also had longer disease-free survival than those in group B (54.6 months vs. 43.5 months, P = 0.014) (Fig. 2). However, no statistically significant differences in overall survival were observed between the 2 groups (55.3 months vs. 69.4 months, P = 0.864) (Fig. 3).


Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage III colon cancer.

Jeong WK, Shin JW, Baek SK - Ann Surg Treat Res (2015)

Disease-free survival rates of both groups. Group A, patients receiving chemotherapy within 3 weeks of surgery; group B, patients receiving chemotherapy after 3 weeks of surgery.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4559614&req=5

Figure 2: Disease-free survival rates of both groups. Group A, patients receiving chemotherapy within 3 weeks of surgery; group B, patients receiving chemotherapy after 3 weeks of surgery.
Mentions: Group A patients also had longer disease-free survival than those in group B (54.6 months vs. 43.5 months, P = 0.014) (Fig. 2). However, no statistically significant differences in overall survival were observed between the 2 groups (55.3 months vs. 69.4 months, P = 0.864) (Fig. 3).

Bottom Line: Although adjuvant chemotherapy reduces the risk of disease recurrence in stage III colon cancer patients, published guidelines do not specify when it should be initiated.The mean disease-free survival of patients receiving adjuvant therapy earlier was 54.6 months, whereas that of patients with later treatment was 43.5 months (P = 0.014).However, no significant differences in overall survival were observed between the 2 groups.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Keimyung University Dongsan Medical Center, Daegu, Korea.

ABSTRACT

Purpose: Although adjuvant chemotherapy reduces the risk of disease recurrence in stage III colon cancer patients, published guidelines do not specify when it should be initiated. This study aimed to assess the effect of adjuvant chemotherapy initiation time on disease recurrence and survival in stage III colon cancer patients undergoing curative surgical resection.

Methods: The medical records of stage III colon cancer patients undergoing curative resection between February 2004 and December 2009 were reviewed.

Results: Of the 133 enrolled patients, 27 (20.3%) began adjuvant chemotherapy within 3 weeks of surgery, whereas 106 (79.7%) did after 3 weeks following surgery. Patients receiving chemotherapy within 3 weeks of surgery were less likely to experience recurrences than those beginning treatment later (11.1% vs. 33%, P = 0.018). The mean disease-free survival of patients receiving adjuvant therapy earlier was 54.6 months, whereas that of patients with later treatment was 43.5 months (P = 0.014). However, no significant differences in overall survival were observed between the 2 groups.

Conclusion: Adjuvant chemotherapy should be initiated as soon as a patient's clinical condition allows. Patients with stage III colon cancer may benefit from adjuvant chemotherapy initiated within 3 weeks of surgery.

No MeSH data available.


Related in: MedlinePlus